Bioventix Plc · LSE:BVXP
Bioventix — Investor Presentation (October 2023)
19 slides from Bioventix's investor presentation, Oct 30, 2023
Slide 1: Bioventix plc
Bioventix plc 30 October 2023
Slide 2: Bioventix plc
1 Bioventix plc 30 Oct 2023 Bioventix
Slide 3: Antibodies and Blood Testing
2 Antibodies and Blood Testing ▪Bioventix creates and manufactures sheep monoclonal antibodies (SMAs). Customers incorporate these antibodies in reagent packs for use on automated blood-testing machines antigen antibody ▪Superior antibodies can facilitate improved tests ▪Bioventix sells liquid “phys
Slide 4: Diagnostic Applications for SMAs
3 Diagnostic Applications for SMAs Vitamin D Thyroid function Fertility Chest pain; heart attack Drug testing (25-OH vitamin D) (thyroxine, T3) (testo, estrogens) (troponin) (THC) ▪Bioventix has a portfolio of ~20 antibodies that are sold globally to in vitro diagnostics (IVD) companies ▪Most have b
Slide 5: Antibodies and Business Dynamics
4 Antibodies and Business Dynamics ▪Projects can be internally driven or sponsored by customers +1 year ▪Bioventix takes about 1 year to create new antibodies Prototype test Old test 2-4 years ▪Even for established diagnostics, customers take 2-4 years to prototype tests, = 3-5 years total conduct f
Slide 6: Key Year End Financials
5 Key Year End Financials £ (‘000) year to year to finnCap 30.6.22 30.6.23 forecast 2022/23 Sales 11,720 12,820 12,800 (+9%) P/(L) before tax 9,280 10,130 10,200 (9%) (adjusted) P/(L) after tax 7,670 8,370 8,000 (9%) (adjusted) Period-end cash 6,130 5,720 5,400 Total regular dividend per share (p) 1
Slide 7: Bioventix
6 ▪Note: Siemens troponin revenues will terminate in June 2032 Bioventix
Slide 8: Sales Commentary for the Period
7 Sales Commentary for the Period ▪ Physical product sales performed well • Some physical product revenue streams are naturally spasmodic • Sales to China remain strong accounting for ~50% of total physical sales. Chinese downstream assay price pressure has increased through aggressive central healt
Slide 9: Longer Term Pipeline Development
8 Longer Term Pipeline Development high Amyloid (Pre-Diagnostics) Tau (Alzheimer’s, own-risk) ← Increasing potential value Secretoneurin (CardiNor) medium Low Industrial biomonitoring Pyrene biomonitoring (benzene, isocyanates) Low Medium high Increasing probability of success → ▪There has been a si
Slide 10: Pipeline Development Commentary
9 Pipeline Development Commentary ▪ Secretoneurin (CardiNor/cardiac): CardiNor continue in their efforts to define the potential utility of secretoneurin diagnostics in cardiac health. A leading line of research is the potential to help clinicians identify heart failure patients that would be suitab
Slide 11: Alzheimer's Disease imaging and biomarkers
10 (A) Tau PET (T) (T) (N) ▪Alzheimer’s is complex and is ▪The disease progresses many different amongst individuals years before symptoms appear ▪Changes at a cell level include ▪Neurodegeneration in the Amyloid PET (A) amyloid plaques outside neurons brain is clear in later disease and tau tangles
Slide 12: Diagnostic Potential
11 Tau PET (T) Diagnostic Potential ▪With the advent of therapies for Alzheimer’s disease, blood tests identifying blood-based biomarkers are likely to be useful Amyloid PET (A) tools. To be useful in the future, blood tests should correlate with or otherwise be additive to more expensive brain scan
Slide 13: Tau-Based Blood Tests: Status
12 Tau-Based Blood Tests: Status ▪ Early detection (A): • pTau217 is considered by many experts in the field to be a leading candidate biomarker for early detection, crucial for identifying potential therapy patients • The University of Gothenburg pTau217 prototype assay using an SMA performs in a s
Slide 14: Tau-Based Blood Tests: Commercialisation
13 Tau-Based Blood Tests: Commercialisation ▪ Market development: • The emergence and adoption of Alzheimer’s therapies during the later 2020 and 2030s will require associated screening and monitoring diagnostic tools • Blood-based biomarkers, once fully validated are likely to play an important rol
Slide 15: Bioventix Strategy
14 Bioventix Strategy ▪ Seek novel clinical diagnostic biomarkers that suit our antibody technology and identify partner collaborator labs (eg Tau & University of Gothenburg) ▪ Continue to focus on antibody technology development • Identify antibody technologies that are compatible with existing cor
Slide 16: Bioventix Lab, Farnham
15 Bioventix Lab, Farnham ▪ Technology development ▪ Purification and assay ▪ Cell culture ▪ Bioreactor production ▪Inflationary pressures have led to price increases of some raw materials ▪Staff continuity has remained high with no recent departures or retirements Bioventix
Slide 17: Bioventix Directors
16 Bioventix Directors ▪Peter Harrison, CEO ▪Ian Nicholson, Chairman ▪>30 years experience of ▪>30 years experience of antibody technology at commercial development within Celltech, KS Biomedix & biotechnology including Bioventix Amersham, Celltech, Chroma, Clinigen, Consort Medical & F2G ▪Peter rem
Slide 18: Significant Shareholders
18 Significant Shareholders Institution Shares % (1000s) Sanford DeLand 755 14.5 Liontrust 571 11.0 Total shares = 5,219,656 (Mar 2023) Gresham House 465 8.9 Peter Harrison 359 6.9 Hargreaves Lansdown Stockbrokers 343 6.6 Rathbones Investment Mgmt (inc Investec) 324 6.2 ▪From permissions, other Dans
Slide 19: Conclusions and Outlook
19 Conclusions and Outlook ▪ Sales of our vitamin D antibody and other core SMAs have been in line with expectations ▪ Troponin revenues have increased significantly ▪ Research work on Tau for Alzheimer’s disease diagnostics continues and we remain excited by the data emerging from our collaboration